D. Boral Capital Reiterates “Buy” Rating for Medicus Pharma (NASDAQ:MDCX)

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating reissued by D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $27.00 price objective on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, October 8th. Zacks Research raised Medicus Pharma to a “hold” rating in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $2.47 on Wednesday. The stock’s 50-day simple moving average is $2.34 and its 200-day simple moving average is $3.11. The firm has a market capitalization of $44.02 million and a PE ratio of -1.84. Medicus Pharma has a fifty-two week low of $1.79 and a fifty-two week high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Sell-side analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current year.

Institutional Trading of Medicus Pharma

A number of hedge funds have recently modified their holdings of the stock. Interchange Capital Partners LLC boosted its stake in shares of Medicus Pharma by 14.0% in the first quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company’s stock worth $6,182,000 after buying an additional 204,706 shares during the last quarter. Armistice Capital LLC purchased a new stake in shares of Medicus Pharma in the first quarter worth about $4,710,000. Guyasuta Investment Advisors Inc. purchased a new stake in shares of Medicus Pharma in the second quarter worth about $230,000. Private Advisor Group LLC purchased a new stake in shares of Medicus Pharma in the first quarter worth about $211,000. Finally, SeaCrest Wealth Management LLC purchased a new position in Medicus Pharma during the second quarter worth approximately $139,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.